Revenues close to €1bn at Irish arm of biotech firm

PRE-TAX profits at the Irish arm of global biotechnology company Genzyme increased 30% to €34.8 million last year, with revenues reaching almost €1 billion.

Accounts filed with the Companies’ Office show that Genzyme Ireland enjoyed the increase in pre-tax profits after revenues increased 24%, from €788.7m to €980.4m, in the 12 months to the end of December last.

Established in Waterford in 2001, Genzyme Ireland is the primary distribution centre for many of Genzyme’s major treatments. Its products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing.